| Pair Name | Curcumin, Lenvatinib | ||
| Phytochemical Name | Curcumin (PubChem CID: 969516 ) | ||
| Anticancer drug Name | Lenvatinib (PubChem CID: 9823820 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Curcumin, Lenvatinib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | EGFR | hsa1956 | |
| Down-regulation | Expression | MTOR | hsa2475 | |
| In Vitro Model | Huh-7 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0336 |
| SNU-449 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0454 | |
| PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0485 | |
| SNU-398 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0077 | |
| SK-HEP-1 | Liver and intrahepatic bile duct epithelial neoplasm | Homo sapiens (Human) | CVCL_0525 | |
| Result | We report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma. Cells. 2023;12(4):612. Published 2023 Feb 14. doi:10.3390/cells12040612. | Click |
